---
title: "Bacopa Extract: Definitive NTRPX Evaluation"
subtitle: "Evidence-Based Selection for the Best Supplement System"
description: "Comprehensive analysis of Synapsa, Cognance, Bacognize, and BacoMind"
status: "FINAL"
philosophy: "Evidence over theory. Proven over promising."
---

# Bacopa Extract: The Definitive NTRPX Evaluation

<Note type="philosophy">
**NTRPX Design Philosophy:** We optimize for outcomes backed by evidence. Novel mechanisms are exciting, but clinical validation is non-negotiable. The best ingredient is one that has been proven to work in humans, not one that should work based on theory.
</Note>

---

## Executive Summary

After comprehensive analysis of the four leading branded Bacopa extracts, the evaluation reveals a clear hierarchy:

| Rank | Extract | Verdict | Rationale |
|------|---------|---------|-----------|
| **1st** | **Synapsa® (CDRI-08)** | **RECOMMENDED** | Deepest clinical evidence, proven across populations |
| 2nd | Cognance® | PROMISING BUT PREMATURE | Novel mechanism, lacks independent human RCTs |
| 3rd | Bacognize® | SOLID ALTERNATIVE | Good evidence, differentiation is quality not mechanism |
| 4th | BacoMind® | INSUFFICIENT DIFFERENTIATION | Marketing claims exceed peer-reviewed evidence |

---

## Detailed Analysis

---

### 1. Synapsa® (CDRI-08) — THE GOLD STANDARD

**Manufacturer:** PLT Health Solutions (originally Central Drug Research Institute, India)  
**Standardization:** ≥55% Bacosides (Bacoside A3, Bacopaside II, Jujubogenin isomer)  
**Clinical Dose:** 300-320mg daily

#### Clinical Evidence Portfolio

Synapsa/CDRI-08 has the most extensive human clinical research of any Bacopa extract:

| Study | Population | Duration | Key Findings |
|-------|------------|----------|--------------|
| Stough 2001 | Healthy adults (n=46) | 12 weeks | Improved speed of visual information processing, learning rate, memory consolidation |
| Roodenrys 2002 | Adults 18-60 (n=76) | 12 weeks | Improved word recall, reduced forgetting |
| Stough 2008 | Healthy adults (n=62) | 90 days | Improved working memory accuracy, reduced RVIP false positives |
| Calabrese 2008 | Elderly 65+ (n=54) | 12 weeks | Improved delayed word recall, Stroop performance, reduced anxiety/depression |
| Downey 2013 | Healthy adults (n=24) | **Acute (single dose)** | 320mg improved Cognitive Demand Battery performance |
| Benson 2014 | Healthy adults (n=17) | **Acute** | Improved multitasking, reduced cortisol response to stress |
| Kean 2022 | Children 6-14 (n=112) | 14 weeks | Improved cognitive flexibility, executive function, sleep |
| McPhee 2021 | Older adults 55+ (n=28) | 12 weeks | Faster spatial working memory RT, combined with cognitive training |

**Meta-Analysis (Kongkeaw 2014):** 9 RCTs, 437 subjects. Bacopa improved cognition, particularly **speed of attention** (p\<0.001).

#### Mechanisms of Action (Validated)

```
┌─────────────────────────────────────────────────────────────────┐
│              SYNAPSA MECHANISM OF ACTION                        │
├─────────────────────────────────────────────────────────────────┤
│                                                                 │
│  ACETYLCHOLINE SYSTEM                                          │
│  ───────────────────                                           │
│  • Inhibits acetylcholinesterase (AChE)                        │
│  • Activates choline acetyltransferase (ChAT)                  │
│  • Increases ACh levels in hippocampus and cortex              │
│                                                                 │
│  SEROTONIN SYSTEM                                              │
│  ────────────────                                              │
│  • Increases 5-HT levels in hippocampus                        │
│  • Modulates TPH2 (tryptophan hydroxylase)                     │
│  • Upregulates SERT (serotonin transporter)                    │
│                                                                 │
│  GABA SYSTEM                                                   │
│  ──────────                                                    │
│  • Enhances GABA-A receptor subunit expression                 │
│  • Upregulates glutamate decarboxylase                         │
│  • Contributes to anxiolytic effect                            │
│                                                                 │
│  NEUROPROTECTION                                               │
│  ───────────────                                               │
│  • Antioxidant (reduces lipid peroxidation)                    │
│  • Anti-inflammatory (reduces TNF-α, IL-6)                     │
│  • Protects against β-amyloid toxicity                         │
│  • Increases BDNF expression                                   │
│                                                                 │
│  SYNAPTIC PLASTICITY                                           │
│  ──────────────────                                            │
│  • Increases dendritic branching (hippocampus)                 │
│  • Enhances long-term potentiation (LTP)                       │
│  • Upregulates GluN2B (NMDA receptor subunit)                  │
│                                                                 │
└─────────────────────────────────────────────────────────────────┘
```

#### Side Effect Profile

| Effect | Incidence | Notes |
|--------|-----------|-------|
| GI discomfort | 15-20% | Nausea, cramping, increased stool frequency |
| Fatigue/sedation | 5-10% | Due to GABA enhancement; typically resolves |
| Dry mouth | ~5% | Mild, transient |

**The Sedation Question:** The GABA-enhancing properties of Synapsa can cause mild sedation in some users. This is:
- A **feature** for evening/sleep products (anxiolytic, sleep quality)
- A manageable **consideration** for daytime use (timing, dose adjustment)

#### NTRPX Verdict: Synapsa®

**RECOMMENDED as primary Bacopa extract.**

**Strengths:**
- ✅ Deepest clinical evidence of any Bacopa extract
- ✅ Proven across multiple populations (adults, children, elderly)
- ✅ Both acute AND chronic effects demonstrated
- ✅ Validated mechanisms of action
- ✅ Strong safety profile
- ✅ Regulatory acceptance (GRAS, NDI)

**Considerations:**
- ⚠️ Takes 4-6 weeks for full cognitive effects
- ⚠️ Mild sedation possible (context-dependent)

---

### 2. Cognance® — THEORETICALLY COMPELLING, CLINICALLY UNPROVEN

**Manufacturer:** Nootropics Depot  
**Standardization:** 10% Ebelin Lactone  
**Clinical Dose:** 100-200mg daily

#### The Ebelin Lactone Theory

Cognance represents a fundamentally different approach to Bacopa. Rather than standardizing to bacosides, it standardizes to **ebelin lactone**, an aglycone derivative formed when bacosides are metabolized.

**The Key Insight (Ramasamy 2015, PLOS ONE):**

| Compound | M1 Muscarinic Ki | 5-HT2A Ki | BBB Penetration |
|----------|------------------|-----------|-----------------|
| Bacosides | No binding | No binding | Poor |
| Jujubogenin | Weak | Weak | Moderate |
| **Ebelin Lactone** | **0.45 μM** | **4.21 μM** | **High** |

This suggests:
1. Bacosides themselves are NOT the active compounds
2. They must be converted to aglycones (like ebelin lactone) in the gut
3. Ebelin lactone has direct CNS receptor activity
4. Ebelin lactone crosses the BBB efficiently

**Proposed Mechanism:**

```
┌─────────────────────────────────────────────────────────────────┐
│              COGNANCE PROPOSED MECHANISM                        │
├─────────────────────────────────────────────────────────────────┤
│                                                                 │
│  5-HT2A RECEPTOR (ALLOSTERIC MODULATION)                       │
│  ──────────────────────────────────────                        │
│  • Positive allosteric modulator (NOT direct agonist)          │
│  • Increases receptor sensitivity to endogenous serotonin      │
│  • Theorized "microdose-like" effects on cognition             │
│  • Enhanced cognitive flexibility, creativity                   │
│                                                                 │
│  M1 MUSCARINIC RECEPTOR (DIRECT AGONISM)                       │
│  ─────────────────────────────────────────                     │
│  • "Holy grail" target for cognition                           │
│  • Selective M1 agonists are rare in nature                    │
│  • Memory and learning enhancement                             │
│                                                                 │
│  CLAIMED ADVANTAGES                                            │
│  ─────────────────                                             │
│  • Faster onset (days vs weeks)                                │
│  • No lethargy (avoids GABA-A activation)                      │
│  • Pre-metabolized = more bioavailable                         │
│                                                                 │
└─────────────────────────────────────────────────────────────────┘
```

#### The Evidence Gap

**What EXISTS:**
- In silico docking studies (Ramasamy 2015)
- In vitro receptor binding assays (Ramasamy 2015)
- Anecdotal reports from users
- Manufacturer's claims

**What DOES NOT EXIST:**
- ❌ Independent human RCTs
- ❌ Peer-reviewed clinical trials on Cognance specifically
- ❌ Head-to-head comparisons vs standard Bacopa
- ❌ Long-term safety data

#### NTRPX Verdict: Cognance®

**NOT RECOMMENDED at this time.**

**Why the theory is compelling:**
- Ebelin lactone's receptor profile is genuinely interesting
- The bioavailability argument is scientifically sound
- The mechanism could explain why traditional Bacopa takes weeks to work

**Why we cannot recommend it:**
- NTRPX standards require clinical proof, not theoretical plausibility
- "Should work" ≠ "proven to work"
- The lack of RCTs means we cannot verify claims of superiority
- Novel extraction process = unknown unknowns

**Future Status:** Cognance may become the answer in 2-3 years with proper clinical validation. Today, it remains promising but unproven.

---

### 3. Bacognize® — SOLID BUT NOT DIFFERENTIATED

**Manufacturer:** Verdure Sciences  
**Standardization:** Bacopa glycosides (proprietary profile)  
**Clinical Dose:** 150mg twice daily (300mg total)

#### Clinical Evidence

| Study | Population | Duration | Key Findings |
|-------|------------|----------|--------------|
| Kumar 2016 | Medical students (n=60) | 6 weeks | Improved cognitive functions |
| Lopresti 2021 | Adults with poor sleep (n=89) | 28 days | Improved emotional wellbeing, general health, reduced sIgA/sAA |

The Lopresti 2021 study is notable for showing:
- **Primary outcome (sleep):** NOT significant vs placebo
- **Secondary outcomes:** Improved emotional wellbeing (+14%), pain reduction, general health
- **Biomarkers:** Reduced salivary IgA and α-amylase (stress markers)

#### NTRPX Verdict: Bacognize®

**ACCEPTABLE ALTERNATIVE, not primary choice.**

**Strengths:**
- Good quality dossier
- Clean label positioning
- Stress/adaptogen evidence

**Limitations:**
- Fewer RCTs than Synapsa
- Differentiation is quality assurance, not novel mechanism
- Primary endpoint (sleep) failed in main trial

---

### 4. BacoMind® — MARKETING > EVIDENCE

**Manufacturer:** Natural Remedies Pvt. Ltd.  
**Standardization:** "Full-spectrum" with 9 bioactives + bacosides  
**Clinical Dose:** 300-450mg daily

#### Clinical Evidence

| Study | Population | Duration | Key Findings |
|-------|------------|----------|--------------|
| Barbhaiya 2008 | Elderly (n=60) | 12 weeks | Improved memory in elderly |
| Usha 2008 | Children requiring IEP | Variable | Cognitive enhancement |

#### NTRPX Verdict: BacoMind®

**NOT RECOMMENDED.**

**Concerns:**
- "Full-spectrum" and "9 bioactives" are marketing terms
- Limited peer-reviewed evidence of superiority vs other extracts
- No clear mechanistic differentiation
- Cannot verify claims against standard Bacopa

---

## The Lethargy Question: Context Matters

A critical consideration for Bacopa selection is the **sedation/lethargy** side effect reported with traditional extracts. This occurs due to GABA-A receptor enhancement.

### The Key Insight: It Depends on the Product

| Product Context | Sedation Is... | Recommendation |
|-----------------|----------------|----------------|
| **Sol (Morning)** | Undesirable | Synapsa at lower dose (150-200mg) or time with caffeine |
| **Luna (Sleep)** | **DESIRABLE** | Synapsa at full dose (300-320mg) — anxiolytic, sleep quality |
| **Focus/Work** | Undesirable | Consider timing (evening dosing builds chronic effects) |
| **Stress/Anxiety** | Desirable | Synapsa's GABA effects are the feature |

**Important:** The sedation effect:
1. Affects only ~5-10% of users
2. Often resolves after 2-4 weeks of use
3. Can be mitigated by timing (evening dosing)
4. Is dose-dependent (lower doses = less sedation)

---

## NTRPX Optimal Integration

### Product-Specific Recommendations

#### SOL (Morning Cognitive Stack)

**Ingredient:** Synapsa® (CDRI-08)  
**Dose:** 150-200mg (lower end to minimize sedation risk)  
**Timing:** With breakfast

**Rationale:**
- Proven cognitive enhancement
- Lower dose mitigates sedation
- Synergy with existing Sol ingredients (creatine, nooLVL)
- Builds chronic cognitive benefits with daily use

**Expected Benefits:**
- Improved working memory accuracy
- Enhanced information processing speed
- Reduced anxiety/stress
- Neuroprotection

#### LUNA (Sleep/Recovery Stack)

**Ingredient:** Synapsa® (CDRI-08)  
**Dose:** 300-320mg (full clinical dose)  
**Timing:** 30-60 minutes before bed

**Rationale:**
- GABA enhancement becomes a **feature** (anxiolytic, sleep quality)
- Full dose maximizes cognitive building effects overnight
- Synergy with Luna's relaxation profile
- Clinical data supports sleep routine improvements (Kean 2022)

**Expected Benefits:**
- Reduced anxiety before sleep
- Improved sleep routine/quality
- Overnight memory consolidation
- Chronic cognitive enhancement (builds over weeks)

---

## Head-to-Head Comparison Matrix

| Criterion | Synapsa® | Cognance® | Bacognize® | BacoMind® |
|-----------|----------|-----------|------------|-----------|
| **Human RCTs** | 10+ | 0 | 2-3 | 2-3 |
| **Meta-analyses** | Yes | No | No | No |
| **Acute effects proven** | Yes | Claimed | Partial | No |
| **Chronic effects proven** | Yes | Unknown | Yes | Yes |
| **Mechanism validated** | Yes | In vitro only | Partial | No |
| **Novel differentiation** | No | Yes | No | No |
| **Sedation risk** | Moderate | Low (claimed) | Moderate | Moderate |
| **Regulatory status** | GRAS, NDI | Newer | GRAS | GRAS |
| **Cost** | Moderate | Premium | Moderate | Moderate |
| **NTRPX Score** | **★★★★★** | ★★★☆☆ | ★★★★☆ | ★★★☆☆ |

---

## Final Recommendation

### Primary: Synapsa® (CDRI-08)

**For NTRPX's "no compromises" standard, Synapsa is the clear choice:**

1. **Evidence Depth:** No other Bacopa extract comes close to Synapsa's clinical validation
2. **Proven Efficacy:** Meta-analyses confirm cognitive benefits
3. **Population Breadth:** Validated in adults, children, and elderly
4. **Mechanism Clarity:** Well-characterized pharmacology
5. **Regulatory Acceptance:** GRAS, NDI, global acceptance
6. **Context Flexibility:** Works for both cognitive (Sol) and sleep (Luna) applications

### Product Integration

| Product | Extract | Dose | Primary Benefit |
|---------|---------|------|-----------------|
| **Sol** | Synapsa® | 150-200mg | Cognitive enhancement, neuroprotection |
| **Luna** | Synapsa® | 300-320mg | Anxiolytic, sleep quality, memory consolidation |

### The Cognance Question

Cognance represents an intellectually compelling hypothesis about Bacopa's mechanism of action. The ebelin lactone theory may prove correct. However:

> **NTRPX does not formulate based on "should work." We formulate based on "proven to work."**

When Cognance has 2-3 independent human RCTs showing superiority over standard Bacopa, we will reconsider. Until then, Synapsa remains the evidence-based choice.

---

## References

1. Stough C, et al. The chronic effects of an extract of Bacopa monniera (Brahmi) on cognitive function in healthy human subjects. *Psychopharmacology.* 2001;156(4):481-484.

2. Roodenrys S, et al. Chronic effects of Brahmi (Bacopa monnieri) on human memory. *Neuropsychopharmacology.* 2002;27(2):279-281.

3. Calabrese C, et al. Effects of a standardized Bacopa monnieri extract on cognitive performance, anxiety, and depression in the elderly: a randomized, double-blind, placebo-controlled trial. *J Altern Complement Med.* 2008;14(6):707-713. [PMC3153866](https://pmc.ncbi.nlm.nih.gov/articles/PMC3153866/)

4. Downey LA, et al. An acute, double-blind, placebo-controlled crossover study of 320 mg and 640 mg doses of a special extract of Bacopa monnieri (CDRI 08) on sustained cognitive performance. *Phytother Res.* 2013;27(9):1407-1413. [PubMed 23281132](https://pubmed.ncbi.nlm.nih.gov/23281132/)

5. Kongkeaw C, et al. Meta-analysis of randomized controlled trials on cognitive effects of Bacopa monnieri extract. *J Ethnopharmacol.* 2014;151(1):528-535. [PubMed 24252493](https://pubmed.ncbi.nlm.nih.gov/24252493/)

6. Ramasamy S, et al. In Silico and In Vitro Analysis of Bacoside A Aglycones and Its Derivatives as the Constituents Responsible for the Cognitive Effects of Bacopa monnieri. *PLOS ONE.* 2015;10(5):e0126565. [PubMed 25965066](https://pubmed.ncbi.nlm.nih.gov/25965066/)

7. Kumar N, et al. Efficacy of standardized extract of Bacopa monnieri (Bacognize®) on cognitive functions of medical students: a six-week, randomized placebo-controlled trial. *Evid Based Complement Alternat Med.* 2016;2016:4103423.

8. Kean JD, et al. Effects of Bacopa monnieri (CDRI 08®) in a population of males exhibiting inattention and hyperactivity aged 6 to 14 years: A randomized, double-blind, placebo-controlled trial. *Phytother Res.* 2022;36(1):528-541. [PubMed 35041248](https://pubmed.ncbi.nlm.nih.gov/35041248/)

9. Lopresti AL, et al. Effects of a Bacopa monnieri extract (Bacognize®) on stress, fatigue, quality of life and sleep in adults with self-reported poor sleep: A randomised, double-blind, placebo-controlled study. *J Funct Foods.* 2021;85:104671.

10. Aguiar S, Borowski T. Neuropharmacological review of the nootropic herb Bacopa monnieri. *Rejuvenation Res.* 2013;16(4):313-326. [PMC3746283](https://pmc.ncbi.nlm.nih.gov/articles/PMC3746283/)

---

**Document Status:** FINAL  
**Date:** January 23, 2026  
**Philosophy:** Evidence over theory. Proven over promising.